NCT01466972 2020-07-08Reversing Hormone Resistance in Advanced Breast Cancer With PazopanibUniversity of California, San FranciscoPhase 2 Completed30 enrolled 11 charts
NCT00722293 2017-11-13A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid TumorsGlaxoSmithKlinePhase 1 Completed111 enrolled